-
(
SabistonD
Sabiston Textbook of Surgery. 20th ed.
Philadelphia, PA: Elsevier; 2016.)
SabistonD
Sabiston Textbook of Surgery. 20th ed.
Philadelphia, PA: Elsevier; 2016.
SabistonD
Sabiston Textbook of Surgery. 20th ed.
Philadelphia, PA: Elsevier; 2016.,
SabistonD
Sabiston Textbook of Surgery. 20th ed.
Philadelphia, PA: Elsevier; 2016.
-
A.
Soran,
V.
Ozmen,
S.
Ozbas,
H.
Karanlık,
M.
Muslumanoglu,
A.
Igci,
Z.
Canturk,
Z.
Utkan,
C.
Ozaslan,
T.
Evrensel,
C.
Uras,
E.
Aksaz,
A.
Soyder,
U.
Ugurlu,
C.
Col,
N.
Cabioğlu,
B.
Bozkurt,
A.
Uzunkoy,
N.
Koksal,
B.
Gulluoglu,
B.
Unal,
C.
Atalay,
E.
Yıldırım,
E.
Erdem,
S.
Salimoğlu,
A.
Sezer,
A.
Koyuncu,
G.
Gurleyik,
H.
Alagol,
N.
Ulufi,
U.
Berberoǧlu,
M.
Dulger,
O.
Cengiz,
E.
Sezgin,
Ronald
Johnson
(2018)
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
Annals of Surgical Oncology, 25
-
D.
Palma,
R.
Olson,
S.
Harrow,
S.
Gaede,
A.
Louie,
C.
Haasbeek,
L.
Mulroy,
M.
Lock,
G.
Rodrigues,
B.
Yaremko,
D.
Schellenberg,
B.
Ahmad,
G.
Griffioen,
S.
Senthi,
A.
Swaminath,
N.
Kopek,
Mitchell
Liu,
K.
Moore,
S.
Currie,
G.
Bauman,
A.
Warner,
S.
Senan
(2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
The Lancet, 393
-
G.
Can
(2019)
Breast Disease: Management and Therapies
-
Cai-Jin
Lin,
Jiayi
Wu,
S.
Ding,
C.
Goh,
L.
Andriani,
Shuangshuang
Lu,
K.
Shen,
Li
Zhu
(2019)
Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery.
Journal of the National Comprehensive Cancer Network : JNCCN, 17 12
-
(
XiaoWZouYZhengS, et al
Primary tumor resection in stage IV breast cancer: a systemic review and meta-analysis. Eur J Surg Oncol. 2018;44:1504-1512.30146252)
XiaoWZouYZhengS, et al
Primary tumor resection in stage IV breast cancer: a systemic review and meta-analysis. Eur J Surg Oncol. 2018;44:1504-1512.30146252
XiaoWZouYZhengS, et al
Primary tumor resection in stage IV breast cancer: a systemic review and meta-analysis. Eur J Surg Oncol. 2018;44:1504-1512.30146252,
XiaoWZouYZhengS, et al
Primary tumor resection in stage IV breast cancer: a systemic review and meta-analysis. Eur J Surg Oncol. 2018;44:1504-1512.30146252
-
(
FitzalFBjelic-RadisicVKnauerM, et al
Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269:1163-1169.31082916)
FitzalFBjelic-RadisicVKnauerM, et al
Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269:1163-1169.31082916
FitzalFBjelic-RadisicVKnauerM, et al
Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269:1163-1169.31082916,
FitzalFBjelic-RadisicVKnauerM, et al
Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269:1163-1169.31082916
-
Anuhya
Kommalapati,
S.
Tella,
G.
Goyal,
A.
Ganti,
J.
Krishnamurthy,
P.
Tandra
(2018)
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer
Breast Cancer Research and Treatment, 170
-
(
AkayCUenoNChisholmG, et al
Primary tumor resection as a component of multimodality treatment may improve local control and survival in stage IV inflammatory breast cancer. Cancer. 2014;120:1319-1328.24510381)
AkayCUenoNChisholmG, et al
Primary tumor resection as a component of multimodality treatment may improve local control and survival in stage IV inflammatory breast cancer. Cancer. 2014;120:1319-1328.24510381
AkayCUenoNChisholmG, et al
Primary tumor resection as a component of multimodality treatment may improve local control and survival in stage IV inflammatory breast cancer. Cancer. 2014;120:1319-1328.24510381,
AkayCUenoNChisholmG, et al
Primary tumor resection as a component of multimodality treatment may improve local control and survival in stage IV inflammatory breast cancer. Cancer. 2014;120:1319-1328.24510381
-
The role of local therapies in metastatic breast cancer . UpToDate
-
M.
Co,
J.
Ng,
A.
Kwong
(2019)
De-novo metastatic breast cancers with or without primary tumor resection - A 10-year study.
Cancer treatment and research communications, 19
-
M.
Teshome
(2018)
Role of Operative Management in Stage IV Breast Cancer.
The Surgical clinics of North America, 98 4
-
Soumitra
Eachempati
(2004)
Sabiston Textbook of Surgery
Surgical Infections, 5
-
(
TeshomeM
Role of operative management in stage IV breast cancer. Surg Clin N Am. 2018;98:859-868.30005779)
TeshomeM
Role of operative management in stage IV breast cancer. Surg Clin N Am. 2018;98:859-868.30005779
TeshomeM
Role of operative management in stage IV breast cancer. Surg Clin N Am. 2018;98:859-868.30005779,
TeshomeM
Role of operative management in stage IV breast cancer. Surg Clin N Am. 2018;98:859-868.30005779
-
R.
Badwe,
R.
Hawaldar,
N.
Nair,
R.
Kaushik,
V.
Parmar,
S.
Siddique,
A.
Budrukkar,
I.
Mittra,
Sudeep
Gupta
(2015)
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
The Lancet. Oncology, 16 13
-
(
SabelMWhiteJHayesDChagparAWazerDVoraS
The role of local therapies in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/the-role-of-local-therapies-in-metastatic-breast-cancer#:~:text=The%20primary%20role%20of%20local,infection%2C%20or%20wound%20management).)
SabelMWhiteJHayesDChagparAWazerDVoraS
The role of local therapies in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/the-role-of-local-therapies-in-metastatic-breast-cancer#:~:text=The%20primary%20role%20of%20local,infection%2C%20or%20wound%20management).
SabelMWhiteJHayesDChagparAWazerDVoraS
The role of local therapies in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/the-role-of-local-therapies-in-metastatic-breast-cancer#:~:text=The%20primary%20role%20of%20local,infection%2C%20or%20wound%20management).,
SabelMWhiteJHayesDChagparAWazerDVoraS
The role of local therapies in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/the-role-of-local-therapies-in-metastatic-breast-cancer#:~:text=The%20primary%20role%20of%20local,infection%2C%20or%20wound%20management).
-
P.
Fasching,
S.
Brucker,
T.
Fehm,
F.
Overkamp,
W.
Janni,
M.
Wallwiener,
P.
Hadji,
E.
Belleville,
L.
Häberle,
F.
Taran,
D.
Lüftner,
M.
Lux,
J.
Ettl,
V.
Müller,
H.
Tesch,
D.
Wallwiener,
A.
Schneeweiss
(2015)
Prognostic and Predictive Factors in Metastatic Breast Cancer
-
(2016)
SEER Fast Stats
-
(
GeraRHage ChehadeHELWazirU, et al
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216066 patients: a meta-analysis. Sci Rep. 2020;10:2952. doi:10.1038/s41598-020-59908-1.32076063)
GeraRHage ChehadeHELWazirU, et al
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216066 patients: a meta-analysis. Sci Rep. 2020;10:2952. doi:10.1038/s41598-020-59908-1.32076063
GeraRHage ChehadeHELWazirU, et al
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216066 patients: a meta-analysis. Sci Rep. 2020;10:2952. doi:10.1038/s41598-020-59908-1.32076063,
GeraRHage ChehadeHELWazirU, et al
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216066 patients: a meta-analysis. Sci Rep. 2020;10:2952. doi:10.1038/s41598-020-59908-1.32076063
-
The role of local therapies in metastatic breast cancer
-
Yao
Wong,
A.
Raghavendra,
C.
Hatzis,
J.
Irizarry,
Teresita
Vega,
N.
Horowitz,
C.
Barcenas,
M.
Chávez-MacGregor,
V.
Valero,
D.
Tripathy,
L.
Pusztai,
R.
Murthy
(2018)
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
The oncologist, 24 3
-
T.
King,
Jaclyn
Lyman,
M.
Gonen,
Sylvia
Reyes,
E.
Hwang,
H.
Rugo,
Minetta
Liu,
J.
Boughey,
L.
Jacobs,
K.
McGuire,
A.
Storniolo,
C.
Isaacs,
I.
Meszoely,
C.
Poznak,
G.
Babiera,
L.
Norton,
M.
Morrow,
A.
Wolff,
E.
Winer,
C.
Hudis
(2016)
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013).
Journal of Clinical Oncology, 34
-
(2019)
Primary surgery in patients with de novo stage IV breast cancer; finalizing the protocol MF07-01 randomized clinical trial. Paper presented at: San Antonio Breast Cancer Symposium
-
(
MayerIBursteinHVoraS
Systemic treatment for metastatic breast cancer: general principles. UpToDate. https://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-general-principles.)
MayerIBursteinHVoraS
Systemic treatment for metastatic breast cancer: general principles. UpToDate. https://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-general-principles.
MayerIBursteinHVoraS
Systemic treatment for metastatic breast cancer: general principles. UpToDate. https://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-general-principles.,
MayerIBursteinHVoraS
Systemic treatment for metastatic breast cancer: general principles. UpToDate. https://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-general-principles.
-
Long-term survival of de novo stage IV HER2 positive breast cancers treated with HER2-targeted therapy
-
F.
Fitzal,
V.
Bjelic-Radisic,
M.
Knauer,
G.
Steger,
M.
Hubalek,
M.
Balić,
C.
Singer,
R.
Bartsch,
P.
Schrenk,
L.
Soelkner,
R.
Greil,
M.
Gnant
(2019)
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial
Annals of Surgery, 269
-
(
LinCWuJDingS, et al
Subdivision of M1 stage for de novo metastatic breast cancer to better predict prognosis and response to primary tumor surgery. J Natl Compr Canc Netw. 2019;17:1521-1528.31805535)
LinCWuJDingS, et al
Subdivision of M1 stage for de novo metastatic breast cancer to better predict prognosis and response to primary tumor surgery. J Natl Compr Canc Netw. 2019;17:1521-1528.31805535
LinCWuJDingS, et al
Subdivision of M1 stage for de novo metastatic breast cancer to better predict prognosis and response to primary tumor surgery. J Natl Compr Canc Netw. 2019;17:1521-1528.31805535,
LinCWuJDingS, et al
Subdivision of M1 stage for de novo metastatic breast cancer to better predict prognosis and response to primary tumor surgery. J Natl Compr Canc Netw. 2019;17:1521-1528.31805535
-
(
KingTALymanJPGonenM, et al
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol. 2016;34:1000-1006.)
KingTALymanJPGonenM, et al
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol. 2016;34:1000-1006.
KingTALymanJPGonenM, et al
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol. 2016;34:1000-1006.,
KingTALymanJPGonenM, et al
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol. 2016;34:1000-1006.
-
(
BadweRHawaldarRNairN, et al
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380-1388.26363985)
BadweRHawaldarRNairN, et al
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380-1388.26363985
BadweRHawaldarRNairN, et al
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380-1388.26363985,
BadweRHawaldarRNairN, et al
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380-1388.26363985
-
(
PalmaDOlsonRHarrowS, et al
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet. 2019;393:2051-2058.30982687)
PalmaDOlsonRHarrowS, et al
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet. 2019;393:2051-2058.30982687
PalmaDOlsonRHarrowS, et al
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet. 2019;393:2051-2058.30982687,
PalmaDOlsonRHarrowS, et al
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet. 2019;393:2051-2058.30982687
-
E.
Pons-Tostivint,
Y.
Kirova,
A.
Lusque,
M.
Campone,
J.
Geffrelot,
C.
Mazouni,
A.
Mailliez,
D.
Pasquier,
N.
Madranges,
N.
Firmin,
A.
Crouzet,
A.
Gonçalves,
Clémentine
Jankowski,
T.
rouge,
N.
Pouget,
B.
Lande,
Delphine
Mouttet-Boizat,
J.
Ferrero,
L.
Uwer,
J.
Eymard,
M.
Mouret-Reynier,
T.
Petit,
M.
Robain,
T.
Filleron,
C.
Cailliot,
F.
Dalenc
(2018)
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis
Annals of Surgical Oncology, 26
-
(
SEER Fast Stats. http://seer.cancer.gov/faststats/.)
SEER Fast Stats. http://seer.cancer.gov/faststats/.
SEER Fast Stats. http://seer.cancer.gov/faststats/.,
SEER Fast Stats. http://seer.cancer.gov/faststats/.
-
Weikai
Xiao,
Yutian
Zou,
Shaoquan
Zheng,
Xiaoqian
Hu,
Peng
Liu,
Xinhua
Xie,
Ping
Yu,
Hailin
Tang,
Xiaoming
Xie
(2018)
Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44 10
-
(
Pons-TostivintEKirovaYLusqueA, et al
Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched analysis. Ann Surg Oncol. 2019;26:356-365.30539492)
Pons-TostivintEKirovaYLusqueA, et al
Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched analysis. Ann Surg Oncol. 2019;26:356-365.30539492
Pons-TostivintEKirovaYLusqueA, et al
Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched analysis. Ann Surg Oncol. 2019;26:356-365.30539492,
Pons-TostivintEKirovaYLusqueA, et al
Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched analysis. Ann Surg Oncol. 2019;26:356-365.30539492
-
(
WongYRaghavendraAHatzisC, et al
Long-term survival of de novo stage IV HER2 positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24:313-318.30139836)
WongYRaghavendraAHatzisC, et al
Long-term survival of de novo stage IV HER2 positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24:313-318.30139836
WongYRaghavendraAHatzisC, et al
Long-term survival of de novo stage IV HER2 positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24:313-318.30139836,
WongYRaghavendraAHatzisC, et al
Long-term survival of de novo stage IV HER2 positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24:313-318.30139836
-
(
SoranAOzmenVOzbasS, et al
Primary surgery in patients with de novo stage IV breast cancer; finalizing the protocol MF07-01 randomized clinical trial. Paper presented at: San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, TX.)
SoranAOzmenVOzbasS, et al
Primary surgery in patients with de novo stage IV breast cancer; finalizing the protocol MF07-01 randomized clinical trial. Paper presented at: San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, TX.
SoranAOzmenVOzbasS, et al
Primary surgery in patients with de novo stage IV breast cancer; finalizing the protocol MF07-01 randomized clinical trial. Paper presented at: San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, TX.,
SoranAOzmenVOzbasS, et al
Primary surgery in patients with de novo stage IV breast cancer; finalizing the protocol MF07-01 randomized clinical trial. Paper presented at: San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, TX.
-
Primary surgery in patients with de novo stage IV breast cancer; finalizing the protocol MF07-01 randomized clinical trial
-
C.
Akay,
N.
Ueno,
G.
Chisholm,
G.
Hortobagyi,
W.
Woodward,
R.
Alvarez,
I.
Bedrosian,
H.
Kuerer,
K.
Hunt,
L.
Huo,
G.
Babiera
(2014)
Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer
Cancer, 120
-
(
ChiaSBursteinHVoraS
Prognostic and predictive factors in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-metastatic-breast-cancer#:~:text=By%20definition%2C%20a%20prognostic%20factor, burden%20%5B5%2C6%5D.)
ChiaSBursteinHVoraS
Prognostic and predictive factors in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-metastatic-breast-cancer#:~:text=By%20definition%2C%20a%20prognostic%20factor, burden%20%5B5%2C6%5D.
ChiaSBursteinHVoraS
Prognostic and predictive factors in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-metastatic-breast-cancer#:~:text=By%20definition%2C%20a%20prognostic%20factor, burden%20%5B5%2C6%5D.,
ChiaSBursteinHVoraS
Prognostic and predictive factors in metastatic breast cancer. UpToDate. https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-metastatic-breast-cancer#:~:text=By%20definition%2C%20a%20prognostic%20factor, burden%20%5B5%2C6%5D.
-
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216066 patients: a meta-analysis
-
(
CoMNgJKwongA
De-novo metastatic breast cancers with or without primary tumor resection: a 10 year study. Cancer Treat Res Commun. 2019;19:1-5.)
CoMNgJKwongA
De-novo metastatic breast cancers with or without primary tumor resection: a 10 year study. Cancer Treat Res Commun. 2019;19:1-5.
CoMNgJKwongA
De-novo metastatic breast cancers with or without primary tumor resection: a 10 year study. Cancer Treat Res Commun. 2019;19:1-5.,
CoMNgJKwongA
De-novo metastatic breast cancers with or without primary tumor resection: a 10 year study. Cancer Treat Res Commun. 2019;19:1-5.
-
Systemic treatment for metastatic breast cancer: general principles
-
Systemic treatment for metastatic breast cancer : general principles . UpToDate
-
J.
Blum,
P.
Flynn,
G.
Yothers,
L.
Asmar,
C.
Geyer,
S.
Jacobs,
N.
Robert,
J.
Atkins,
J.
O’Shaughnessy,
C.
Dang,
H.
Gómez,
L.
Fehrenbacher,
S.
Vukelja,
A.
Lyss,
D.
Paul,
A.
Brufsky,
S.
Swain,
E.
Mamounas,
Stephen
Jones,
N.
Wolmark
(2016)
Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br
Journal of Clinical Oncology, 34
-
(
AydinerAIgciASoranA.
Breast Disease: Management and Therapies (Vol. 2). 2nd ed.
Cham, Switzerland: Springer; 2019.)
AydinerAIgciASoranA.
Breast Disease: Management and Therapies (Vol. 2). 2nd ed.
Cham, Switzerland: Springer; 2019.
AydinerAIgciASoranA.
Breast Disease: Management and Therapies (Vol. 2). 2nd ed.
Cham, Switzerland: Springer; 2019.,
AydinerAIgciASoranA.
Breast Disease: Management and Therapies (Vol. 2). 2nd ed.
Cham, Switzerland: Springer; 2019.
-
(
KommalapatiATellaSGoyalG, et al
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. Breast Ca Res. 2018;170:677-685.)
KommalapatiATellaSGoyalG, et al
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. Breast Ca Res. 2018;170:677-685.
KommalapatiATellaSGoyalG, et al
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. Breast Ca Res. 2018;170:677-685.,
KommalapatiATellaSGoyalG, et al
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. Breast Ca Res. 2018;170:677-685.
-
R.
Gera,
H.
Chehade,
U.
Wazir,
S.
Tayeh,
A.
Kasem,
K.
Mokbel
(2020)
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis
Scientific Reports, 10